Drs. Ray Deshaies and William DeGrado: Keynote Speakers at the 2023 BioPacific Conference
South San Francisco, CA – The Chinese American Bio/Pharmaceutical Society is delighted to unveil Dr. Raymond Deshaies and Dr. William DeGrado as keynote speakers of the upcoming 2023 BioPacific Conference. The event will take place at the South San Francisco Convention Center on October 28th, 2023.
Dr. Raymond Deshaies holds the position of Senior Vice President of Global Research at Amgen. In his lecture titled "Multispecific Medicines for the Future," Dr. Deshaies will delve into the challenges, opportunities, and Amgen's innovative approaches in developing the next generation of multispecific small molecule and biologic medicines.
Dr. William DeGrado is a distinguished Professor in the Department of Pharmaceutical Chemistry at the University of California San Francisco. In his lecture titled "De novo Protein Design of Functional Proteins," Dr. Degrado will share his profound insights on the remarkable strides made in creating predictable protein structures and functions.
The 2023 BioPacific Conference promises a convergence of groundbreaking ideas, pioneering research, and networking opportunities. This event is an invaluable occasion for professionals and enthusiasts to engage with these distinguished experts and explore the cutting-edge advancements shaping the future of bio/pharmaceuticals.
For media inquiries and press registration, please contact: email@example.com
About Dr. Raymond Deshaies
Dr. Raymond Deshaies
Raymond Deshaies, Ph.D. is Senior Vice President of Global Research at Amgen. Prior to joining Amgen, Dr. Deshaies served as a professor at the California Institute of Technology (Caltech) and an executive officer in Caltech’s Division of Biology and Biological Engineering.
He was also an investigator at the Howard Hughes Medical Institute. He has published over
150 papers on various subjects including discoveries of Sec61 translocon, cullin–RING ubiquitin ligases, and proteolysis-targeting chimeric molecules (Protacs).
In addition to his academic work, Deshaies co-founded Proteolix in 2003. In 2011, he co-founded Cleave Therapeutics.
Deshaies holds a bachelor's degree in biochemistry from Cornell University and a Ph.D. in biochemistry from the University of California, Berkeley. He is also a member of the American Academy of Arts and Sciences and National Academy of Sciences. In 2022, Fierce Pharma named Deshaies as one of the most influential people in biopharma. He received the 2023 Jacob and Louise Gabbay Award in Biotechnology and Medicine along with Yale University professor, Craig Crews, for their pioneering work on PROTACs, or proteolysis targeting chimeras.
About Dr. William DeGrado
Dr. William DeGrado
Dr. William (Bill) DeGrado’s work focuses on the design of small molecule drugs, peptides, and proteins to address biological and mechanistic questions.
Since 2011, Bill has been a professor in the Department of Pharmaceutical Chemistry at the University of California, San Francisco, where he is also a member of the Cardiovascular Research Institute and an adjunct member of the Institute for Neurodegenerative Diseases. He is also a Chair Professor at Sungkyunkwan University (Korea) as well. Prior to UCSF, he was a member of DuPont Central Research and DuPont Merck Pharmaceutical Company from 1981 to 1996, and the Raiziss Professor in the Department of Biochemistry and Biophysics at the University of Pennsylvania (1996 – 2011).
Bill is a member of the National Academy of Science, the National Academy of Inventors, the American Academy of Arts and Sciences, and a fellow of the American Association for the Advancement of Science. He is also a past President of the Protein Society. Bill was also a co-founder of Pliant Therapeutics, a company devoted to finding cures for fibrotic diseases (http://pliantrx.com). Pliant went public in 2020.
Some of Bill’s research interests include: de novo design of proteins and peptides; peptide mimetics; protein mis-folding diseases; structure/function of membrane proteins, including integrins and viral ion channels; small molecule drug design; and bioinorganic chemistry.
Special Shout-out to Our BioPacific Conference 2023 Sponsors
RSVP – $0 (USD)